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Key points 
x The population-based Swedish Prescribed Drug Register (SPDR) and National Patient 
Register (NPR) are excellent sources of information for epidemiological association 
studies. 
x Asthma medication reported in the SPDR is a suitable proxy for asthma both in 
children and adults, but the same approach is insufficient for eczema. 
x The quality of asthma diagnoses in the NPR can be considered high, since 
approximately all school-age children fulfilled predefined criteria of asthma. 
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Abstract 
 
Purpose 
Validated measures of asthma and eczema at the population level remain a challenge. Our aim 
was to ascertain if register-based information on asthma/eczema medication can function as a 
proxy for an asthma/eczema diagnosis and to validate register-based asthma diagnoses. 
Methods 
Information was requested on all 0-45 year old individuals with reported asthma/eczema 
medication and/or diagnoses in the Swedish Prescribed Drug Register and National Patient 
Register, between July 2005 and December 2009 (N=250,691). Medical records for 1,952 
individuals were reviewed to estimate the proportion of individuals with 1) asthma/eczema 
medication that fulfilled predefined criteria of asthma/eczema (positive predictive value 
(PPV); 2) a register-based asthma diagnosis verified as asthma by set criteria. 
Results 
PPV for asthma by predefined criteria ranged between 0.75 (95% CI: 0.70-0.78) to 0.94 (95% 
CI: 0.91- 0.96) depending on age-group. PPV for eczema was estimated to 0.45 (95% CI: 
0.38-0.51). Eighty percent of children 0-4.5 years and 99% of children >4.5-17 years with a 
register-based diagnosis of asthma were verified as asthmatics.  
Conclusion 
Asthma medication is a suitable proxy for asthma in older children and adults; the same 
approach is insufficient for eczema. This validation study of two Swedish registers opens for 
future large nation-wide register-based studies on asthma.  
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Introduction 
Asthma and eczema are two of the most common chronic childhood diseases in the world 1, 2. 
Asthma is an inflammatory disease of the airways with a prevalence of about 8-10% in 
children and 6-8% in adults in Sweden 3, 4. Eczema, manifesting as chronic itchy flexural 
rashes affects about 20% of all Swedish children 2.  
Valid measures of asthma and eczema at the population level remain a challenge 
5. Most epidemiological studies investigating asthma and eczema have previously used 
questionnaires to identify these diseases 6. Questionnaires are often restricted to specific areas 
or age-groups and can be susceptible to culture- and language-related issues associated with 
translation and interpretation 7, 8. Due to ethical, economical and practical reasons a 
standardized clinical examination of individuals with and without asthma/eczema is not 
feasible in large-scale studies. Thus, validated population-based register data can function as a 
proxy, when aiming to study the diseases in the total population.  
The Swedish National Board of Health and Welfare (NBHW) holds several 
population-based health registers, such as the Swedish Prescribed Drug Register (SPDR) 9 
and the National Patient Register (NPR) 10, covering the entire Swedish population (9 million 
inhabitants). Since July 2005, all dispensed prescriptions are reported to the SPDR. All 
diagnoses from the in-patient care and 75% of specialized out-patient care are reported to the 
NPR since 1964 and 2001 respectively, whereas diagnoses from primary health care centres 
(PHCC) are not recorded on a national level. To identify individuals with asthma and eczema 
in Sweden that have visited a physician at a PHCC, these diagnoses could be conveniently 
identified in the SPDR which allows identification of specific drugs for treatment of specific 
diseases.  
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 Previous studies have validated asthma medication as a proxy for asthmatic 
disease in children 11-14 and adults 14-16 by reviewing medical records from general 
practitioners (GPs) 12, 15, 16 or through retrospective questionnaires to GPs 11 and paediatricians 
13 in limited regions. Others have suggested that prescription prevalence of asthma medication 
could function as a measure of disease prevalence in children 17 and adults 18. Until now, there 
is no population-based study that has used randomly selected medical records on a national 
level to validate an asthma diagnosis with pre-defined criteria based on dispensed 
prescriptions of asthma medications. Some Swedish studies have already used asthma 
medication as a proxy for asthmatic disease 19-22, but so far no one has validated the Swedish 
data. Additionally, the authors have not been able to identify any study that has investigated 
the opportunity of using prescription data on eczema medication as a proxy for eczema.   
To enhance the strength and quality of register-based research and in order to 
obtain generalizable findings in large populations, validation of register data is needed. 
Therefore, the aim of this study was to 1) describe the utilization of asthma/eczema 
medication in Sweden; 2) validate if medication for asthma/ eczema can function as a proxy 
for an asthma/eczema diagnosis respectively, by reviewing medical records corresponding to 
dispensed medications in the SPDR, according to doctor-diagnoses and predefined criteria by 
the Swedish  Paediatric  Society’s  section  for  Allergy  23; and 3) validate asthma diagnoses in 
children in the NPR, by investigating how a reported diagnosis of asthma corresponds to set 
criteria 23.  
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Method 
Study design and population 
This was a nationwide population-based register study using information from the SPDR, the 
NPR and medical records from PHCC and hospitals all around Sweden.  
The SPDR is one of the largest population-based drug registers in the world 9. It 
provides complete data on dispensed drugs regardless of age, gender, prescribing physician 
and reimbursement status. All pharmaceuticals are classified according to the Anatomical 
Therapeutic Chemical classifications system (ATC). The NPR includes information on 
primary and secondary diagnoses, according to the International Classification of Disease 
(ICD) system. The universal use of the personal identity number (PIN) 24 enables a linkage 
between the SPDR and NPR. 
Encrypted information on all individuals, 0-45 years of age, that had filled at 
least one prescription of asthma and/or eczema medication (aim 1) and/or had been given a 
diagnosis of asthma (ICD 10 code J45) and/or eczema (ICD 10 code L20) between July 2005 
and December 2009, was requested from the NBHW. Information  on  the  patients’  age,  sex,  
prescription- and dispensing date, data on dispensed item and amount (SPDR) and discharge 
date (NPR), was also requested. Medications of interest were inhalations of selective β2-
adrenoreceptor agonists (ATC: R03AC), glucocorticoids (R03BA) and fixed combinations of 
β2-agonists and glucocorticoids (R03AK), leukotriene receptor antagonists (R03DC),  
glucocorticoids for external use (D07A) and the immunosuppressant tacrolimus (D11AH01) 
and pimecrolimus (D11AH02). Oral  β2-agonists (R03C) were not included.  
Figure 1 displays the linkage between the SPDR and the NPR and the inclusion 
criteria for the study population. To validate asthma/eczema medication in the SPDR as a 
proxy for an asthma/eczema diagnosis, all individuals with filled prescriptions of 
asthma/eczema medication without a diagnosis of asthma/eczema in the NPR, were identified 
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and grouped based on the age at the date of a given prescription (asthma-medication: 0-4.5; 
>4.5-17; 18-45 years; eczema-medication: 0-17 years), as well as number of filled 
prescriptions and type of prescribed medication. The reason for excluding individuals with a 
diagnosis of asthma/eczema was to ascertain the possibility of using SPDR as a 
complementary source of information to the NPR. To avoid one-time asthma medication 
users, at least two or more prescriptions were needed, as well as with a time frame of two 
weeks between prescriptions for the pre-school children. To validate the diagnosis of asthma 
in the NPR two groups of children (0-4.5; >4.5-17 years) with a diagnosis of asthma, 
independent of history of asthma medication, were furthermore identified.  
Collection and assessment of medical records 
Random samples from all groups were sent to NBHW and PINs requested. The study 
participants’  medical  records  corresponding  to  the  dates  of prescriptions of the asthma/eczema 
medication (aim 2), or corresponding to the discharge date from the hospital (aim 3), were 
requested by a letter to the head of the unit/ward where the patient had been treated. Two 
reminder letters were sent out before the end of data collection.  
The diagnosis that each patient had been assigned by the physician at each 
consultation connected to the date of the prescribed medication was extracted from the 
medical records. Diagnoses of special interest for the asthma part were asthma (J45), acute 
bronchitis/bronchiolitis (J20/J21) and chronic bronchitis/chronic obstructive pulmonary 
disease (COPD) (J42/J44).  
Furthermore, medical records belonging to pre-schoolers (0 – 4.5 years) and 
school-age children (>4.5 – 17) in the asthma medication validation and asthma diagnosis 
validation, were combined and  reviewed by authors AÖ and CA according to the criteria of 
asthma set by the Swedish Paediatric Society 23,  where  asthma  is  defined  as  ≥  3  obstructive  
periods before two years of age and/or;;  ≥  1  obstructive  period  after  two  years  of  age  and/or;;  ≥  
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1  obstructive  period  independent  of  age  when  the  child  has  ≥  1  of  the  following:  eczema,  
allergy or no improvement between periods of respiratory tract infections. Children under two 
years of age  with  ≤  2  asthma-like symptoms during respiratory tract infections, without 
symptoms between infections, were defined as suffering from obstructive bronchitis. 
Individuals without recorded patient history (eg. only a renewal of a prescription) in any 
medical record were excluded in the analysis of PPV based on the criteria by the Swedish 
Paediatric Society. 
Records in the eczema part were firstly reviewed to assess whether the child had 
the  “umbrella  diagnosis”  dermatitis,  which  was  defined  as  either  having been assigned the 
diagnosis unspecific dermatitis (L30.9) by a physician or if having been given either sub-
diagnosis of dermatitis such as eczema (L20), allergic/non-allergic contact dermatitis (L23-
L25) or seborrhoeic dermatitis (L21) assigned by the physician. Secondly, each assigned sub-
diagnosis of dermatitis was analysed separately.  
 
Statistical analysis 
To describe the utilization of asthma/eczema medication in Sweden, period prevalence of 
drug users was estimated as the proportion of individuals in the Swedish population for whom 
medication was dispensed during year 2008. The number of individuals were retrieved from 
Statistics Sweden 25.  
Incidence estimates were based on all new users of anti-asthmatic drugs between 
2008-2009 and estimated person-time based on population data from Statistics Sweden 25 with 
95% confidence intervals calculated assuming poisson distribution. The time period was 
based on the waiting-time distribution 26, which is a frequency distribution of first time 
occurrences of drug use within a time-window. Figure 2 shows the monthly frequencies of 
first appearances of filled prescriptions for all persons who have redeemed anti-asthmatic 
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prescriptions July 2005-December 2009, according to the appearance of their first filled 
prescription within the period. In the beginning of the period there is a mixture of old and new 
users.  The  frequencies  thereafter  decrease  until  it  levels  out.  At  this  point  it’s  mostly  new  
(incident) users that appear. The time period used for incidence estimation has to be beyond 
this point in time to avoid prevalent users to be included in the calculations.  
To validate reported asthma/eczema medication in the SPDR as a proxy for an 
asthma/eczema diagnosis, positive predictive value (PPV) was estimated as the proportion of 
children and adults that had been given a diagnosis of asthma/eczema (as well other asthma-
like and dermatitis-like diagnoses) in each medication validation group with asthma/eczema 
medication. PPV was also estimated as the proportion of pre-schoolers and school-age 
children with asthma medication that fulfilled the criteria of asthma set by the Swedish 
Paediatric Society. The sample size in each group was determined based on an expected PPV 
of 75% and aim of 95% confidence intervals of ± 5%-units.   
To validate the diagnosis of asthma in children in the NPR, the proportion of 
children that had been given a diagnosis by a physician that fulfilled the criteria of asthma, 
was calculated.  
Statistical Analysis Software 9.3 (SAS Institute, Cary, NC) was used for all 
analyses. The study was approved by the Regional Ethical Review Board in Stockholm, 
Sweden.  
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Results 
Prevalence and incidence 
Table 1 shows the period prevalence of anti-asthmatic drugs in year 2008 in Sweden. In total, 
282,826 individuals between 0-45 years of age redeemed approximately 890,000 prescriptions 
of anti-asthmatic drugs. The period prevalence decreased from 7.8% in pre-school children to 
5.9% in school-age children and 4.7 % in adults. Males were more commonly prescribed 
asthma medication in childhood, whereas females dominated in adulthood. The most 
commonly prescribed anti-asthmatic drug in all age groups was inhalations of selective β2-
adrenoreceptor agonists. Table 1 also displays the numbers for drugs used to treat eczema. 
The period prevalence of drugs against eczema also decreased with increasing age. Mild 
glucocorticoids (GC) was the most commonly filled drug against eczema in children 0-4.5 
years, moderate GC in children >4.5-17 years and potent GC in adults. 
Figure 2 presents  the  number  of  “new”  unique  subjects  having  redeemed  anti-
asthmatic drugs for each month July 2005-December 2009. The incidence of new anti-
asthmatic drug users was assessed after a wash-out period of 30 months. The estimated 
number of person-years 2008-2009 in pre-school children was 980,011; in school-age 
children 2,865,921; and in adults 6,874,703. In total, 36,779 pre-school children were defined 
as new users during 2008-2009 thus rendering an incidence of 3.75/100 person-years (95% 
Confidence Interval (CI): 3.71- 3.79). For school-age children the number of new users was 
55,261 corresponding to an incidence of 1.93/100 person-years (95% CI: 1.91-1.94) and in 
adults 102,487 users were found to give an incidence of 1.49/100 person-years (95% CI: 1.48-
1.50).  
Asthma medication as a proxy for asthma diagnosis 
Table 2 displays number of identified individuals in each study group, number of individuals 
for whom medical records were requested and retrieved. In total 250,691 individuals fulfilled 
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the  inclusion  criteria  and  requests  for  2,600  patients’  medical  records  were  sent  out.  In total, 
998 units/wards for the asthma medication validation; 330 for the eczema medication 
validation; and 119 for the asthma diagnosis validation, were contacted. We obtained data on 
1,952 patients (75%). 
Table 2 also shows the response rates of received medical records, where the 
highest response rates were found in pre-schoolers (0-4.5 years: 87%) and school-age children 
(>4.5-17 years: 83%) in the validation of asthma diagnoses in the NPR. The lowest response 
rate of 66% corresponds to school-age children in the asthma medication validation.  
Reasons for no response were; 1) head of unit did not want to participate in study; 2) health 
care centre has ceased to exist; 3) no medical charts could be found at the unit; 4) requests 
were sent in return. 
Table 3 displays the PPV in the asthma medication validation, for a doctor-
diagnosis  of  asthma  and  other  “asthma-like”  diseases  such  as  acute/chronic  bronchitis  in  
received medicals records. PPV for a doctor-diagnosed asthma was 89% in both school-age 
children (4.5-17 years) and adults (18-45), whereas PPV for pre-schoolers was 68%. The PPV 
for doctor-diagnosed acute bronchitis/bronchiolitis in pre-schoolers was 26%, while a PPV of 
less than one percent was seen for COPD/chronic bronchitis independent of age group. The 
groups based on type of diagnosis, are not mutually exclusive since more than one record per 
patient was requested, and each record was reviewed to identify the diagnosis given at each 
consultation.   
Among pre-school children without an asthma diagnosis recorded in any 
medical record (n=166), approximately 38% had been given a diagnosis of acute 
bronchitis/bronchiolitis by their physicians. Corresponding number in school-age children 
was 14% (9 of 66). Three adults had been given a COPD diagnosis at one consultation, but all 
three had also been given a diagnosis of asthma at other occasions (not tabulated).  
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Table 3 also shows PPV based on the asthma criteria by the Swedish Paediatric 
Society, assessed by combined information from all retrieved medical records for each 
individual. The pre-schoolers had a PPV of 75% for asthma, while school-age children (>4.5-
17 years) had a PPV of 94%. When combining pre-schoolers defined as asthmatics with 
children defined as having obstructive bronchitis, PPV increased to 87%. Approximately 6% 
(31 of 486) of pre-school children and 9% (34 of 395) of school-age children had missing 
information on the indication of the prescription and were therefore excluded in the analysis 
of PPV based on asthma criteria for children. Corresponding number for missing information 
in adults was 19% (44 of 234).  
Of the pre-school children that did not fulfil the asthma criteria, 18% (84 of 455; 
after exclusion of individuals with missing information) were defined as having obstructive 
bronchitis by criteria, and 7% (32 of 455) as having been given asthma medication for other 
reasons such as cough or upper respiratory tract infections. All school-age children that did 
not fulfil the asthma criteria (6%) had been given a prescription for other reasons (not 
tabulated).  
Eczema medication as a proxy for eczema diagnosis 
Table 4 shows  PPV  for  the  “umbrella  diagnosis”  dermatitis  and  the  sub-diagnoses eczema, 
seborrhoeic dermatitis and contact dermatitis found in medical records based on medication in 
the SPDR. A PPV of 82% was estimated for dermatitis, while PPV was estimated to be 45% 
for the specific diagnosis of eczema (L20). Approximately 7% (17 of 242) of the children 
included in the eczema medication validation were lacking information on the indication for 
the prescription. 
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Validation of asthma diagnoses in the NPR 
In the validation of a asthma diagnoses in children in the NPR, about 78% of the pre-
schoolers (0-4.5 years) fulfilled the asthma criteria set by the Swedish Paediatric Society. The 
ones that did not fulfil the asthma criteria were almost all defined as suffering from 
obstructive bronchitis (21%). In school-age children (>4.5-17 years) almost everyone (99%) 
fulfilled the asthma criteria (not tabulated).  
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Discussion 
Our results show relatively high positive predictive values for asthma in all age groups which 
suggest that asthma medication reported in the SPDR can function as a suitable proxy for a 
doctor-diagnosed asthma, as well as for asthma by criteria according to the Swedish 
Paediatric Society. Our results bring new possibilities to study asthma in all children and 
young adults in Sweden and support previous findings in association studies which have used 
asthma medication as an indicator for asthma 19-22. Furthermore, the quality of doctor-
diagnosed asthma in the NPR can be considered to be high, since almost eighty percent of 
pre-school children and all school-age children with asthma reported in the NPR fulfilled the 
asthma criteria set by the Swedish Paediatric Society. 
Previous studies on asthma medication as a proxy for asthmatic disease 11-16, 18, 27 
have been restricted to small sample sizes 14, specific regions 11, 13, 16 or used prescribed 
medications instead of filled prescriptions of medication 12, 15. The novelty with this study is 
the population-based design, where randomly selected medical records on a national level 
have been reviewed both to assess doctor-diagnosed asthma and asthma by criteria. Concerns 
against asthma medication as a proxy for asthma have been that asthma medication is often 
prescribed to wheezing infants and the response to the drugs is used as a diagnostic tool for 
asthmatic symptoms 28. Therefore, we only included individuals with at least two records of 
prescribed asthma medication.  
In this first study to evaluate eczema medications as a proxy for a diagnosis of 
eczema,  PPV  for  the  “umbrella  diagnosis”  of  dermatitis  was  rather  high.  On  the other hand, 
the PPV estimated for an eczema diagnosis specifically was quite low. This indicates that 
using eczema medication as proxy for eczema may induce misclassification bias and the 
proxy should be used with caution. The World Allergy Organization recommends that under 
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the  “umbrella  term”  dermatitis,  eczema  should  replace  the  intermediate  term  atopic  
eczema/dermatitis syndrome. Further classification into atopic eczema should only be made 
after determination of Immunoglobulin E, antibodies or skin prick testing 29. Review based on 
validated standardized definitions for eczema 30 was impossible due to lacking information 
and we could only calculate PPV for all diagnoses under the umbrella term dermatitis and 
each sub-diagnosis separately.  
This is the first study to show population-based data on the utilization of anti-
asthmatic drugs in Swedish children and so far, there are no studies to our knowledge that 
have shown population-based data on utilization of drugs to treat eczema. Questionnaire-
based studies with parental reports of atopic eczema have a prevalence of approximately 20% 
2. This is a much higher number than the prescription prevalence for any investigated eczema 
medication in the present study. In Sweden, over-the-counter (OTC) drugs for treatment of 
eczema can be purchased and it is possible that children with mild symptoms might have 
either not been treated at all or have only used OTC drugs and are therefore not included in 
our data.  
The main strengths of this study include our nationwide population-based study 
design and the randomly selected patients to be included in the review of their medical 
records. By using random sampling, we were able to avoid selection bias in terms of regional 
differences and socio-economic status affecting prescribing habits 26. The SPDR is 
population-based and provides complete data. Even though our study period is limited to the 
start of the SPDR in 2005, we were able to avoid influences of seasonal variance. 
Furthermore, the medical records in the medication validation of asthma were both reviewed 
in terms of doctor-diagnosis of asthma and based on criteria. 
We were not able to estimate PPV for different types of asthma, which is one 
limitation in this study. Furthermore, our results with a lower PPV for asthma in pre-
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schoolers, could represent the widely recognized picture of young wheezers 31. A diagnosis of 
asthma becomes more accurate with increasing age 28 and while our criteria for asthma is one 
of  this  study’s  strengths,  it  can  also  be  questioned since it includes both children with 
infection-induced symptoms some of which have signs of allergy, and a group of children 
with allergic asthma with varying prognosis 32. However, the obstructive symptoms for 
infection-induced and allergic asthma are fairly similar. Furthermore, children with infection-
induced asthma belong to the majority of children with asthma in hospital care 33, and are 
important to include in a proxy for the disease to identify as many true asthmatics as possible, 
independent on their prognosis.  
There was a slight difference in PPV between a doctor-diagnosis of asthma and 
asthma according to our criteria in the validation of asthma medication, which could be 
explained by the fact that we were able to combine information from several medical records, 
giving us the possibility to study the patient over time. Our values of PPV would probably 
have increased if we had access to medical records from other occasions than just for the 
consultation where a prescription was given, due to that asthma is a chronic disease and 
physicians might not give the patient a diagnosis at each consultation; neither prescribe 
medication at each visit where a diagnosis is given. The snap-shot study design can also 
explain why not all children with an asthma diagnosis in the NPR could be verified as 
asthmatics.  
In the adult population, less than two percent had been given a diagnosis of 
COPD by their physicians, which corresponds to previous reported prevalence of COPD in 
young adults in the European Community Respiratory Health Survey 34. We cannot dismiss 
the fact that the adults, where an indication for a prescription was missing, did not suffer from 
COPD.  However, by excluding adults above 45 years of age, the risk that COPD has biased 
our results, is diminished. 
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In conclusion, our study suggests that asthma medication in the SPDR can be 
used as proxy for asthma, but not for eczema. This validation study of two Swedish registers 
opens for future large nation-wide register-based studies on asthma.  
 
Acknowledgments  
First, we direct our great appreciation to Gerd Agerberg who have contributed with excellent 
data collection and management. Financial support was provided through the regional 
agreement on medical training and clinical research (ALF) between Stockholm County 
Council and Karolinska Institutet, grants from the Swedish Research Council (grant numbers 
80748301 and 2011-3060) and the Strategic Research Program in Epidemiology at Karolinska 
Institutet. CA was granted the ERS Romain Pauwel Research Award in 2011.  
 
 
18 
 
References  
1. Lai C, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. Global variation in the 
prevalence and severity of asthma symptoms: Phase Three of the International Study of 
Asthma and Allergies in Childhood (ISAAC). Thorax. 2009. 
2. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global 
variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy 
Clin Immunol. 2009; 124(6): 1251-8 e23. 
3. Wennergren G. The prevalence of asthma has reached a plateau. Acta Paediatr. 
2011; 100(7): 938-9. 
4. Ekerljung L, Andersson A, Sundblad BM, Ronmark E, Larsson K, Ahlstedt S, et 
al. Has the increase in the prevalence of asthma and respiratory symptoms reached a plateau 
in Stockholm, Sweden? Int J Tuberc Lung Dis. 2010; 14(6): 764-71. 
5. Hansen S, Strom M, Maslova E, Mortensen EL, Granstrom C, Olsen SF. A 
comparison of three methods to measure asthma in epidemiologic studies: results from the 
danish national birth cohort. PLoS One. 2012; 7(5): e36328. 
6. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. 
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. 
Eur Respir J. 1995; 8(3): 483-91. 
7. Flohr C, Weinmayr G, Weiland SK, Addo-Yobo E, Annesi-Maesano I, 
Bjorksten B, et al. How well do questionnaires perform compared with physical examination 
in detecting flexural eczema? Findings from the International Study of Asthma and Allergies 
in Childhood (ISAAC) Phase Two. Br J Dermatol. 2009; 161(4): 846-53. 
8. Smeeton NC, Rona RJ, Oyarzun M, Diaz PV. Agreement between responses to 
a standardized asthma questionnaire and a questionnaire following a demonstration of asthma 
symptoms in adults. Am J Epidemiol. 2006; 163(4): 384-91. 
9. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, 
Bergman U, et al. The new Swedish Prescribed Drug Register--opportunities for 
pharmacoepidemiological research and experience from the first six months. 
Pharmacoepidemiol Drug Saf. 2007; 16(7): 726-35. 
10. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et 
al. External review and validation of the Swedish national inpatient register. BMC Public 
Health. 2011; 11: 450. 
11. Moth G, Vedsted P, Schiotz P. Identification of asthmatic children using 
prescription data and diagnosis. Eur J Clin Pharmacol. 2007; 63(6): 605-11. 
12. Zuidgeest MG, van Dijk L, Smit HA, van der Wouden JC, Brunekreef B, 
Leufkens HG, et al. Prescription of respiratory medication without an asthma diagnosis in 
children: a population based study. BMC Health Serv Res. 2008; 8: 16. 
19 
 
13. Bianchi M, Clavenna A, Sequi M, Bonati M. Asthma diagnosis vs. analysis of 
anti-asthmatic prescriptions to identify asthma in children. Eur J Clin Pharmacol. 2011; 67(9): 
967-8. 
14. Osborne ML, Vollmer WM, Johnson RE, Buist AS. Use of an automated 
prescription database to identify individuals with asthma. J Clin Epidemiol. 1995; 48(11): 
1393-7. 
15. Pont LG, van der Werf GT, Denig P, Haaijer-Ruskamp FM. Identifying general 
practice patients diagnosed with asthma and their exacerbation episodes from prescribing 
data. Eur J Clin Pharmacol. 2002; 57(11): 819-25. 
16. Himmel W, Hummers-Pradier E, Schumann H, Kochen MM. The predictive 
value of asthma medications to identify individuals with asthma--a study in German general 
practices. Br J Gen Pract. 2001; 51(472): 879-83. 
17. Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence 
and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription 
study. Eur J Clin Pharmacol. 2010; 66(4): 399-406. 
18. Haupt D, Wettermark B, Nilsson JL. Dispensed volumes of anti-asthmatic drugs 
related to the prevalence of asthma and COPD in Sweden. Pharmacoepidemiol Drug Saf. 
2008; 17(5): 461-7. 
19. Dehlink E, Yen E, Leichtner AM, Hait EJ, Fiebiger E. First evidence of a 
possible association between gastric acid suppression during pregnancy and childhood 
asthma: a population-based register study. Clin Exp Allergy. 2009; 39(2): 246-53. 
20. Braback L, Vogt H, Hjern A. Migration and asthma medication in international 
adoptees and immigrant families in Sweden. Clin Exp Allergy. 2011; 41(8): 1108-15. 
21. Almqvist C, Wettermark B, Hedlin G, Ye W, Lundholm C. Antibiotics and 
asthma medication in a large register-based cohort study - confounding, cause and effect. Clin 
Exp Allergy. 2012; 42(1): 104-11. 
22. Aspberg S, Dahlquist G, Kahan T, Kallen B. Confirmed association between 
neonatal phototherapy or neonatal icterus and risk of childhood asthma. Pediatr Allergy 
Immunol. 2010; 21(4 Pt 2): e733-9. 
23. Paediatric  Society’s  section  for  Allergy.  Asthma  in  children  - terminology and 
diagnoses. http://www.barnallergisektionen.se/stenciler_nya06/b1_astmadefinitioner.html 
Date last updated: 2006. Date last accessed: October 9 2012. Web page in Swedish.   [cited; 
Available from:  
24. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish 
personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J 
Epidemiol. 2009; 24(11): 659-67. 
20 
 
25. Statistics Sweden. Swedish population between 1860-2011. 
http://www.scb.se/Pages/ProductTables____25795.aspx. Date last updated: February 20 
2012. Date last accessed: October 9 2012.   [cited; Available from:  
26. Arnlind MH, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson EW. 
Regional variation and adherence to guidelines for drug treatment of asthma. Eur J Clin 
Pharmacol. 2009. 
27. Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic 
medications as a proxy for prevalence of asthma in children and adolescents in Norway: a 
nationwide prescription database analysis. Eur J Clin Pharmacol. 2007; 63(7): 693-8. 
28. Zuidgeest MG, Smit HA, Bracke M, Wijga AH, Brunekreef B, Hoekstra MO, et 
al. Persistence of asthma medication use in preschool children. Respir Med. 2008; 102(10): 
1446-51. 
29. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. 
Revised nomenclature for allergy for global use: Report of the Nomenclature Review 
Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 
113(5): 832-6. 
30. Simpson EL, Keck LE, Chalmers JR, Williams HC. How should an incident 
case of atopic dermatitis be defined? A systematic review of primary prevention studies. J 
Allergy Clin Immunol. 2012; 130(1): 137-44. 
31. Grad R, Morgan WJ. Long-term outcomes of early-onset wheeze and asthma. J 
Allergy Clin Immunol. 2012; 130(2): 299-307. 
32. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to 
define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 
2000; 162(4 Pt 1): 1403-6. 
33. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. 
Community study of role of viral infections in exacerbations of asthma in 9-11 year old 
children. Bmj. 1995; 310(6989): 1225-9. 
34. de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, et al. Risk 
factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J 
Respir Crit Care Med. 2011; 183(7): 891-7. 
 
 
21 
 
Tables 
Table 1. Period prevalence (year 2008) of anti-asthmatic/eczema medication* in children and 
adults 0-45 years of age.  Number of individuals in each age group in the Swedish population 
was retrieved from Statistics Sweden ¥. 
 Age group 
 0-4.5 >4.5-17 18-45 
Asthma (R03)*  
Total number of individuals 37 826 84 598 160 402 
Sex (n, %)    
      Male 23 362 (61.8) 48 383 (57.2) 68 426 (42.7) 
      Female 14 464 (38.2) 36 215 (42.8) 91 976 (57.3) 
 
Total number of filled prescriptions for drugs for 
obstructive airway disease  
134 021 253 758 499 704 
Prevalence (%) Male; Female       
Drugs for obstructive airway diseases 9.4 6.1 6.5 5.2 3.9 5.5 
Inhalations of selective β2-adrenoreceptor 
agonists 
4.8 3.1 3.3 2.9 2.1 3.0 
Adrenergics and other drugs for obstructive 
airway diseases, combinatios 
0.1 0.04 1.0 0.7 0.8 1.0 
Inhalation of corticosteroids 4.0 2.7 1.9 1.4 0.9 1.3 
Leukotriene receptor antagonists 0.3 0.2 0.3 0.2 0.1 0.1 
       
Eczema (D07A, D11AH01, D11AH02)*       
Total number of individuals 32 757 55 307 141 728 
Sex (n, %)    
      Male 18 116 (55.3) 27 277 (49.3) 59 241 (41.8) 
      Female 14 641 (44.7) 28 030 (50.7) 82 487 (58.2) 
 
Total number of filled prescriptions of 
glucocorticoids for external use  
54 238 8900 243 740 
Total number of filled prescriptions of topical 
immunosuppressants  
577 2536 6038 
Prevalence (%) Male; Female        
Glucorticoids for external use 7.2 6.2  3.6 3.9 3.3 4.9 
Glucorticoids for external use, mild (1)  3.8 3.2 0.9 1.0 0.3 0.5 
Glucorticoids for external use, moderate (2)  2.4 2.2 1.2 1.5 0.8 1.2 
Glucorticoids for external use, potent (3) 0.8 0.7 1.2 1.4 2.0 2.7 
Glucorticoids for external use, very potent (4)  0.2 0.02 0.4 0.1 0.3 0.4 
Tacrolimus  0.1 0.1 0.1 0.1 0.1 0.1 
Picremolimus  0.02 0.02 0.01 0.02 0.01 0.02 
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¥   Swedish population in 2008:  
 
0-4.5   years: 249,052 (males); 235,537 (females) 
4.5-17 years: 739,293 (males); 700,958 (females) 
18-45  years: 1,744,498 (males); 1,671,429 (females) 
 
 
* Description of ATC codes for pharmaceuticals 
 
R03 – drugs for obstructive airway diseases  
R03AC – selective β2-adrenoreceptor agonists 
R03AK – fixed  combinations  of  β2-agonists and corticosteroids  
R03BA – inhalations of corticosteroids   
R03DC – Leukotriene receptor antagonists 
D07 – glucorticoids for external use 
D07AA – glucorticoids for external use, group 1 
D07AB – glucorticoids for external use, group 2 
D07AC – glucorticoids for external use, group 3 
D07AD – glucorticoids for external use, group 4 
D11AH01 – immunosuppressant Tacrolimus 
D11AH02 – immunosuppressant Picremolimus 
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Table 2. Study base that fulfilled inclusion criteria (N) in each group and number of patients for whom medical records were requested and 
retrieved.  
 
 Anti-asthmatic drugs  
SPDR 
Eczema drugs 
SPDR 
Asthma diagnosis  
NPR 
Age years (group) 
 
0-4.5 (1) 
 
>4.5 – 17 (2) 
 
18-45 (3) 
 
0-17 (4) 
 
0-4.5 (5) 
 
>4.5 -17 (6) 
 
Study base, N 10  001 16  853 128  747 40  364 28 248 26 478 
Number of patients for whom medical 
records were requested, n 
600 600 350 350 350 350 
 
Number of patients for whom medical 
records were retrieved, n (%) 
486 (81.0) 395 (65.8) 234 (66.9) 242 (69.1) 306 (87.4) 289 (82.6) 
Sex, n (%)       
        Male 281 (57.8) 203 (51.4) 93 (39.7) 115 (47.5) 202 (66.0) 155 (53.6) 
       Female 205 (42.2) 192 (48.6) 141 (60.3) 127 (52.5) 104 (34.0) 134 (46.4) 
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Table 3. Positive Predictive Value (PPV) and 95% Confidence Interval (CI) estimated as the 
proportion of individuals with asthma medication with a doctor-diagnosed asthma or asthma-
like diagnoses. PPV and 95% CI estimated as the proportion of pre-schoolers and school-age 
children with asthma medication that fulfilled the criteria of asthma or asthma in combination 
with obstructive bronchitis according to criteria by the Swedish Paediatric Society. 
       
 Age (years) 
 0-4.5  >4.5-17 18-45  
Doctor-diagnosis 
n;  PPV (95% CI) 
      
 
Asthma (J45) 
 
 
320 
 
0.68  
(0.64-0.72) 
 
329 
 
0.89 
 (0.85-0.92) 
 
171 
 
0.89  
(0.83-0.93) 
 
Acute Bronchitis and 
bronchiolitis (J20/J21) 
123 0.26  
(0.22-0.30) 
16 0.04  
(0.02-0.07) 
11 0.06  
(0.03-0.10) 
Chronic bronchitis and 
COPD (J42/J44) 
1 0.002  
(0.0001-0.01) 
0 - 3 0.02  
(0.003-0.04) 
Diagnosis by criteria*¥  
n;  PPV (95% CI) 
      
 
Asthma  
 
 
 
339 
 
 
 
0.75  
(0.70- 0.78) 
 
 
340 
 
 
 
0.94  
(0.91- 0.96) 
 
 
- 
 
 
 
- 
 
Asthma or obstructive 
bronchitis  
 
415 
 
 
 
0.87  
(0.83- 0.90) 
 
 
- 
 
- 
 
- 
 
- 
 
* ≥  3  obstructive  periods  before  2  years  and/or    ≥1  obstructive  period  after  2  years  and/or    ≥ 1 obstructive period 
independent of age, where the child has eczema, food allergy, other allergies, or if the child does not get better 
between periods of respiratory tract infections. Children under two years of age with asthma-like symptoms 
during respiratory tract infections, but without symptoms between infections, were defined as suffering from 
obstructive bronchitis.   
 
¥ Individuals where no information was available at all, were excluded in the analysis of PPV based on criteria. 
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Table 4. Positive Predictive Value (PPV) and 95% Confidence Interval (CI) estimated as the 
proportion of children 0-17 years of age with filled prescriptions of pharmaceuticals of topical 
glucocorticoids or immunosuppressants that were assessed as having a diagnosis of unspecific 
dermatitis and sub-diagnoses of dermatitis. 
 
  
 Age (years) 
 0-17 
Diagnosis     n          PPV (95% CI ) 
Dermatitis* 199 0.82 (0.77-0.87) 
 
       Eczema (L20) 108 0.45 (0.38-0.51) 
 
       Seborrhoeic dermatitis (L21) 17 0.07 (0.04-0.11) 
 
       Contact dermatitis (L25);       
       allergic (L23) and non-    
       allergic (L24) 
     7 0.03 (0.02-0.06) 
 
*Includes all children who were reviewed as either having been given a diagnosis of unspecific dermatitis 
(L30.9)  by  their  physician  specifically  or  if  having  been  assigned  any  of  the  other  diagnosis  under  the  “umbrella  
diagnosis”  of  dermatitis,  such  as  eczema, seborrhoeic dermatitis and contact dermatitis.  Since all children with a 
sub-diagnosis of dermatitis are included in the group dermatitis, PPV for all groups together exceeds 100%.     
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National Patient 
Register
Prescribed Drug 
Register
Group 1: 0 – 4.5 yrs
≥  2 of ICS and/or LRTA and/or β2-ICS, with 
≥  2  weeks  gap between distributions 
and/or
≥  3  of  ICS  and/or  LRTA  and/or    β2-ICS 
and/or  β2,  within  a  12-month-period
without J45 diagnosis
Group 2: >4.5 – 17 yrs and 
Group 3: 18 – 45 yrs
≥  2  of  ICS  and/or  LRTA  and/or    β2-ICS, 
independent on time between distributions
and/or
≥  3  of  ICS  and/or  LRTA  and/or    β2-ICS 
and/or  β2,  within  a  12-month-period
without J45 diagnosis
Group 4: 0 – 17 yrs
≥  2  of  GC  group  2-4 or
≥  2  of    tacrolimus/picremolimus or
≥  1  of  GC  group  2-4  +  ≥    1  of  GC  group  1  or
≥  1  of  GC  group  2-4  +    ≥  1  of  tacrolimus/  
picremolimus or
≥  1  of    tacrolimus/picremolimus +  ≥    1  of  
GC group 1
without L20 diagnosis
Group 5: 0 – 4.5 yrs
ICD 10: J45 
Group 6: >4.5 – 17 yrs
ICD 10: J45 
Figures 
Figure 1. Through a linkage between the Swedish Prescribed Drug Register and National Patient 
Register, six groups of individuals were identified based on age at prescription, type and number of 
filled prescriptions of asthma/eczema medication without a diagnosis of asthma/eczema (aim 2: group 
1-4), or based on a diagnosis of asthma independent on history of medication (aim 3: group 5 and 6). 
The figure displays inclusion criteria for each group (1-6). 
 
 
 
ICS - Inhalations of corticosteroids (R03BA) 
LRTA – Leukotriene receptor antagonist (R03DC) 
β2-ICS – fixed  combinations  of  β2-agonists and corticosteroids (R03AK) 
β2  – inhalations  of  β2-adrenoreceptor agonists (R03AC) 
GC – glucocorticoids for external use (1) mild; (2) moderate; (3) potent; (4) very potent (D07A) 
Tacrolimus - immunosuppressant (D11AH01) 
Picremolimus - immunosuppressant (D11AH02)  
J45 - ICD 10 for asthma diagnosis 
L20 - ICD 10 for eczema diagnosis 
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Figure 2. Number of individuals with first time filled prescriptions of ATC group R03 
(excluding R03C), for children and adults each month, between July 2005 and December 
2009. The years of 2008-2009 were considered in the analysis of incidence. 
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